Rib-X Reports Additional Positive Delafloxacin Data at ICAAC, Including Performance against New Objective Endpoints …

Rib-X Pharmaceuticals, Inc., today presented new efficacy and safety results from the Company’s Phase 2b clinical trial of delafloxacin for the treatment of acute bacterial skin and skin structure infections , including infections caused by methicillin- and quinolone- resistant Staphylococcus aureus .

Leave a Reply

Your email address will not be published.